Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07436728 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-505 in Adults With Solid Tumors
A Phase 1 study, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
NCT07436728 is a Phase 1 study that is actively recruiting participants, run by Takeda. The registered enrollment target is 151 participants.
The verdict
NCT07436728, a Phase 1 study, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
Study Summary
Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the body (called metastatic), and doctors may not always be able to completely remove them with surgery (called unresectable). This study is a first in human (or FIH) study, which means that this is the first time that the medicine, TAK-505, is given to a smaller group of adults with solid tumors of certain cancer types, such as stomach cancer (gastric adenocarcinoma), cancer of the large bowel (colorectal cancer or CRC), lung cancer (non-small lung cell cancer or NSCLC) and cancer in the mouth, throat or voice box (head and neck squamous cell carcinoma or HNSCC). The main aims of this study are to learn how safe TAK-505 is, how well it works, how well adults with solid tumors tolerate it and to find the dose of TAK-505 that works best with the least side effects. Other aims are to learn how TAK-505 moves through the body (pharmacokinetics (PK)), if it can shrink or slow cancer (preliminary antitumor activity) and to find out if it causes the body's defense system to react to it (immunogenicity).
Interventions
- DRUG TAK-505
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2030-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07436728
The ClinicalTrials.gov registry entry for NCT07436728 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-505 is the first listed.
NCT07436728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07436728 about?
NCT07436728 is a clinical study titled "A Study of TAK-505 in Adults With Solid Tumors". Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the bo...
What is the current status of trial NCT07436728?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2026-05-11. Estimated completion is 2030-08-18.
What interventions are being tested in trial NCT07436728?
The interventions under investigation include: TAK-505 (DRUG).
Who is sponsoring clinical trial NCT07436728?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.